Iambic Therapeutics’ Post

✨ ✨ ✨ I'd like to kick off a new series highlighting some of the best and brightest across the Life Science space ✨ ✨ ✨   My first instalment of this kicks off with a company doing incredible work in the Drug Design space... 🥁 🥁   Exscientia   🔎 They utilise precision information derived from patient tissues alongside sophisticated AI technology to source optimised drug profiles for research. This integrated system has been the first to demonstrate improved clinical outcomes in oncology, and I believe that is just the beginning in their revolution.   📈 They currently have four targets at pre clinical, and phase 1-2, across Haematology, Oncology, and Inflammatory Diseases. With 40% of total clinical growth within Biotech/ Pharmaceuticals sitting within Oncology in 2023, Exscientia should be on your radar!   🗞 With the recent appointment of Marie-Louise Fjaellskog, and promotion of John Overington, I can't wait to see the continued success of this truly pioneer company. #Biotech #innovation #AI #DrugDesign

Great panel discussion between MassiveBio, Nucleai, and PathAI on commercialization and implementation of AI in precision oncology today at Tri-Con. Collaboration amongst our brightest companies and minds in AI is the better way to move quickly to revolutionizing healthcare. Thanks Ben Glass Arturo LoAIza-Bonilla MD Oscar Puig and John Mattison

Rubedo Life Sciences has spent the last six years meticulously laying the groundwork for its pipeline of senescent cell-targeting treatments -- a field that grabbed headlines in the late 2010s for its anti-aging potential. "We didn't want to rush, we wanted to make sure that we were solid before embarking into clinical development. And now we are ready," CEO Marco Quarta told me. Now, flush with a $40-million series A, the biotech plans to enter the clinic this year with its lead senolytic to treat atopic dermatitis and psoriasis: diseases with unmet patient need, carefully selected as the best to demonstrate clinical proof-of-concept. For more on how Rubedo has navigated the senescent cell space, read here: https://lnkd.in/g23Ens2h

Thank you Elizabeth Eaton for this wonderful article covering Rubedo Series A!

Welcome Andrew Lo to the n-Lorem Board of Directors. His expertise in creating novel economic models that provide solutions for cost of care for rare illnesses could open the door for more nano-rare patients to receive treatment. Andrew is a co-founder of BridgeBio Pharma, QLS Advisors, Quantile Health, and Uncommon Cures; a director of AbCellera, Atomwise, BridgeBio, Uncommon Cures, and Vesalius; and a member of the advisory board to the American Cancer Society’s BrightEdge Impact Fund. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery, especially for rare and ultra-rare diseases; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel reimbursement models for creating a robust gene and cell therapy ecosystem. https://lnkd.in/gMSvtV-H

Ever wondered how biotech companies manage to prioritize speed while avoiding siloed data and ensuring efficient data revisiting? 🚀 Discover Ken Steadman, PhD's journey as a Principal Scientist at Plexium Therapeutics and how he and his team are addressing these challenges by leveraging the power of Omics Playground for their omics data analysis. With a faster, flexible, and more creative approach, they achieved: ✅ Rapid data retrieval and reanalysis. ✅ Efficient biomarker identification. ✅ Simplified extraction of insights from complex data. Curious to learn more? Dive into Ken's story and explore how Omics Playground is helping streamline omics data analysis in his pursuit of cancer drug discovery 🧬 Read more at 👉 https://lnkd.in/ehr9PCPb #bioinformatics #computationalbiology #omicsdata #cancerresearch #drugdiscovery #cancerdrugdiscovery #biotech

🚀 Exciting News for the Global Community! 🌐 Today, I'm thrilled to share a passion project that has been close to my heart and is now taking shape as the #First4Founders initiative. 🌟 At the core of this endeavor is my unwavering commitment to inspiring scientists, medical doctors, and biotech founders across the globe. I'm delighted to unveil a new milestone: the launch of our series, "Listen To The Biotech Expert," supported by great Strategic Advisors at CharaBio. 🎙 Episode 1 features Dr. Francesco Marincola, CSO at Sonata Therapeutics (a Flagship Pioneering company) With 30+ years of experience in #oncology and #immunology across various modalities—from #smallmolecules to groundbreaking #celltherapy —Dr. Marincola's insights are a treasure trove for anyone passionate about advancing the frontiers of biotech. We will dive into the differences in R&D for a small molecule drug compared to cell therapies. His previous experience as CSO at Kite Pharma (Gilead’s Cell Therapy Division) adds an extra layer of depth to our conversation. And I look forward to learning more about Sonata’s Network Medicines™ that reprogram diseased cells to instead release curative signals, resulting in durable disease resolution 🔥 And the excitement doesn't end here! I'm thrilled to announce that our next virtual fireside chat will dive into the realm of #businessdevelopment in #Pharma. 🌐 #staytuned for tomorrow's big reveal as we unveil the next expert who will grace our platform. 🌍 To the #scientists , #medicaldoctors, and #biotechentrepreneurs: This initiative is for you. There is no limit to the what you can accomplish, the boundaries you can push in medicine, and the impact you can make. Let's come together, learn from each other, and continue driving the future of biotech. 🚀 Join us on this incredible journey! Have you got a question for Dr. Marincola? Feel free to email or DM me and we will select 3-5 questions from the registered attendees Francesco Marincola Link to the event here https://lnkd.in/dx3W9XHQ #First4Founders #biotechinnovation #ListenToTheExpert #CharaBio #BiotechLeaders #firesidechat

🚨 Breaking news 🚨 iktos acquires SYNSIGHT, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery. As Yann Gaston-Mathe, CEO and Co-founder of Iktos comments « The acquisition of Synsight enables Iktos to expand its platform to new modulators of Protein-Protein interaction’s and RNA-Protein Interaction’s, historically highly challenging targets, thereby addressing major unmet medical needs in various therapeutic areas such as cancer and neurodegenerative diseases » The merger further complements Iktos' AI-based drug discovery platform, that currently includes generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by adding the key step of automated biological testing thanks to MT Bench technology originally developed at INSERM. 👉 To learn more about this acquisition: https://lnkd.in/ez7hHmM8 #drugdiscovery #artificialintelligence #proteinproteininteractions #RNAinteractions Genopole Medicen Paris Region

💊⚕️ The Arqus International Innovators Awards finals took place on 27th June, during the Born Global Start-up Festival (BGSF) in Leipzig. The 4th Arqus International Innovator Award (previously known as the Virtual Company Creation Challenge) went to Karion Therapeutics from the Universidade do Minho. 👩⚕️🩺 Karion is #developing a novel drug candidate for #aggressive #cancers with an unprecedented mode of action. Unlike any other in the market, this drug candidate has a hashtag #highly #effective and #safe #profile, allowing to extend #cancer #patient #survival and #improve #patients’ #quality of #life. More than 700 people from all over #Europe voted and selected their favourite #entrepreneurial team among the different final candidates. #innovation #AICEP #talent #cancer #technology #health #science #medicine #Minho #Portugal

Sharing the transformative power of AI-Immunology™ 🙌   Yesterday, Evaxion’s founder and chief AI officer, Andreas Holm Mattsson, took center stage today at the AI-driven Drug Discovery Summit. Addressing an audience of over 200 leaders from pharma and biotech, Andreas shed light on the game-changing potential of our AI-Immunology™ platform, emphasizing its role in reshaping vaccine development to be faster, cost-effective, and safer💡 Today, he was honorably selected to act as Chair of the morning session🪑 At Evaxion, we take pride in having already demonstrated the precision and predictive power of our AI-Immunology™ platform in oncology and infectious diseases. This seamless integration of AI predictions with both pre-clinical and clinical outcomes is a testament to the power of our proprietary platform and the promise it holds for helping patients globally 🌍💙    Curious to hear more? Dive deeper into the world of AI-Immunology™ and uncover our diverse pipeline products by clicking the link below! 👇  🔗 https://lnkd.in/dfTVx4xQ #AI #AIDrivenDrugDevelopment #Immunotherapy #Biotech